MARKSANS PHARMA (NSE: MARKSANS) gained 6.2% to Rs 250.71 on Tuesday, 9 June 2026, in active trade.
The move at a glance
- Day change: +6.21% to Rs 250.71
- The stock is about 7% below its 52-week high of Rs 271 and 62% above its 52-week low of Rs 155.
- One-year return: -7%
- Today's volume was roughly 0.6 times its recent daily average.
Latest reported financials
| Period | Revenue (Rs Cr) | Net Profit (Rs Cr) |
|---|---|---|
| Q4 FY26 | 891 | 149.0 |
| FY26 (full year) | 2,951 | 420.1 |
In Q4 FY26, revenue rose about 1129% from a year earlier to Rs 891 Cr and net profit came in at Rs 149.0 Cr. For the full year FY26, revenue grew about 1025% to Rs 2,951 Cr.
What is behind the move
Recent coverage on the stock includes: "Marksans Pharma to acquire Netherlands-based QliniQ to strengthen European presence" (BusinessLine, 2026-06-01).
Key ratios
P/E 27.1, ROE 25.7%, Debt/Equity 0.01, Dividend yield 0.34%, Promoter holding 43.9%.
--- This article is for educational purposes only and is not investment advice. The figures above are drawn from company filings and exchange data and may contain errors, restatements or timing differences, so please verify against the primary source before relying on them. Stocks Sena is not a SEBI-registered investment adviser.